Natco Pharma files generic Olaparib tablets in US

Feb 13, 2023

Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer. It is marketed in the US by AstraZeneca under brand...

Zydus Launches IBYRA, the Generic Version of Olaparib, Brings Both Access and Affordability for Cancer Patients in India

Mar 14, 2024

Ahmedabad (Gujarat) [India], March 14: In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor,...